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Abstract
Background:  In selected patients with peritoneal carcinomatosis from colorectal cancer
prognosis can be improved by hyperthermic intraperitoneal chemotherapy (HIPEC) after
cytoreductive surgery. The aim of this study was to evaluate the tumor response of peritoneal
carcinomatosis in tumor-bearing rats treated with HIPEC.
Methods: CC531 colon carcinoma (2,5 × 106 cells), implanted intraperitoneally in Wag/Rija rats,
was treated by hyperthermic intraperitoneal chemotherapy. After 10 days of tumor growth the
animals were randomized into five groups of six animals each: group I: control (n = 6), group II:
sham operated animals (n = 6), group III: hyperthermic intraperitoneal perfusion (HIP) without
cytostatic drugs, group IV: HIPEC with mitomycin C in a concentration of 15 mg/m2 (n = 6), group
V: mitomycin C i.p. alone in a concentration of 10 mg/m2 (n = 6). After 10 days the extent of tumor
spread and histological outcome were analysed by autopsy.
Results:  All control animals developed extensive intraperitoneal tumor growth. Histological
tumor load was significantly reduced in group III and group V and was lowest in group IV. In group
II tumor load was significantly higher than in group I. Implanted metastases were significantly
decreased in group IV compared with group I and group II.
Conclusion:  These findings indicate that HIPEC is an effective treatment for peritoneal
carcinomatosis in this animal model. HIPEC reduced macroscopic and microscopic intraperitoneal
tumor spread.
Background
Gastrointestinal malignancies frequently recur with meta-
static disease limited to the abdominal cavity. The perito-
neal failure rate among patients who present with
recurrence after colon cancer resection is approximately
25–35% [1].
Peritoneal dissemination of colon cancer cells is a com-
mon cause of morbidity and mortality in recurrent disease
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that may result in intestinal obstruction, ascites and intes-
tinal fistula. The median survival time after manifestation
of peritoneal carcinomatosis is about 6–9 months [2].
Peritoneal seeding from colorectal cancer is relatively
resistant to systemic chemotherapy. A treatment strategy
for these patients would be hyperthermic intraperitoneal
chemotherapy (HIPEC). The first clinical hyperthermic
chemotherapy in the treatment of peritoneal carcinoma-
tosis (PC) was performed by Spratt et al. in 1980 [3]. This
therapeutic design is regarded as one of the best options
for the therapy of peritoneal metastasis from gastrointes-
tinal carcinoma. The feasibility of intraperitoneal therapy
has been demonstrated by several groups which used this
technique in combination with cytoreductive surgery to
treat peritoneal carcinomatosis [4,5].
Macroscopic complete resection of PC followed by HIPEC
is potentially capable of curing selected patients present-
ing with disease confined to the peritoneum. The goal of
cytoreductive surgery is to achieve a nearly total resection
of all tumor tissue. In selected patients, HIPEC may lead
to a five-year overall survival of 27% in PC [6].
Although the technique of hyperthermic intraperitoneal
chemoperfusion in humans has been employed in cancer
therapy. In clinical trials human populations are very het-
erogeneous and animal models potential differences are
less. In this study, HIPEC was evaluated in an experimen-
tal tumor bearing rat model.
Methods
Animals
To investigate HIPEC a rat model was used first described
by Martin et al. and modified in our research group [7].
Maintenance and care of all experimental animals were
carried out according to the guidelines of the local respon-
sible Animal Protection Commission and carried out in
compliance with national guidelines (National Institute
of Health for Use of Laboratory Animals; Nr. 621-
2531.31-5/03). 30 inbred male pathogen-free WAG (Wis-
tar Albino Glaxo) rats (Charles River, Sulzbach, Germany)
of reproductive age weighing 200 to 240 g, (Sulzfeld, Ger-
many), were used in this study. They were fed a standard
laboratory diet and tap water ad libidum. The animals were
kept in individual cages during the experiment with a 12
hours light and dark cycle and room temperature of 25°C,
with a relative humidity of 55 per cent.
Tumor model
The tumor cell line used (German Cancer Research Cen-
tre, Heidelberg, German)y was an adenocarcinoma of the
rat colon. These immunocompetent tumor cell line
(CC531) was derived from a G2 differentiated colon car-
cinoma induced by 1,2-dimethylhydrazine [8].
To control for possible mutations of cell lines, only cul-
tures that had undergone less than 10 passages were used
in the experiments. Intraperitoneal tumor application was
performed with a tumor suspension produced in vitro.
The tumor cell line was cultivated at 37°C and 5% CO2 in
an incubator in 20 ml complete medium (RPMI 1640
[Gibco, Life Technologies, Eggenstein, Germany], 10%
fetal bovine serum [Seromed, Biochrom, Berlin, Ger-
many] and 1% Penicillin/Streptomycin [Seromed]). After
three days, cells were detached with 3 ml trypsin (0.25%).
Vitality was evaluated in a Bürker hematocytometer after
the addition of trypan blue. Viability always exceeded 95
per cent. After vital counting, the suspension had a density
of 2,5 × 106 vital cells/200 μl suspension before being
injected into the animals.
In all rats, tumor cell implantation was achieved via a 6
cm laparotomy. The rats were anaesthetized by Isoflurane
inhalation (Baxter, Unterschleißheim, Germany). The
tumor cell suspension was injected under the capsule of
the peritoneal surface in the right upper side of the abdo-
men as described before [7].
The animals were randomised into five groups of six ani-
mals each:
group I: control
group II: sham operated animals
group III: hyperthermic intraperitoneal perfusion (HIP)
without cytostatic drugs,
group IV: HIPEC with mitomycin C in a concentration of
15 mg/m2
group V: mitomycin C i.p. alone in a concentration of 10
mg/m2
10 days after tumor inoculation, the animals from group
II-V underwent a further laparotomy as described. In
group II and III perfusion was performed. In group II the
tumor remainded untreated. In group V mitomycin C was
aplivated intraperitonally in 5 ml saline. Saline was not
removed. Abdomen was open for 90 minutes in groups III
and V.
Compared to the clinical situation, the MMC ratio in our
experimental trial was 1,5:1 (HIPEC versus i.p. therapy).
This was performed as discribed before [7].BMC Cancer 2006, 6:162 http://www.biomedcentral.com/1471-2407/6/162
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Perfusion system
The HIPEC system is a closed circuit, allowing perfusate
circulation with a variable dynamic flow of 40–50 ml/
minute. The warmed perfusate (500 ml) was driven by a
roller pump with two synchronously running pump-
heads on a single axis for the inflow and the outflow lines
(Masterflex®). An inflow catheter was inserted into the
upper abdomen between the hepatic and diaphragmatic
surface, and an outflow catheter was placed within the
pouch of Douglas.
The intraperitoneal temperature was maintained between
40,5 and 41°C. Baseline temperature was recorded for 5
minutes before treatment. Temperature was continuously
measured during application. In group I (control), group
II (sham operated group) and group V (MMC only) tem-
perature measurement was not performed.
Perfusion was performed over 90 minutes after the per-
fusion fluid had reached the required temperature. The
body surface of the animals was calculated according the
formula (A(m2) = mk
0,425 × 1K
0,725/139.315 (m2 = body
surface; mk = body lenght 1K = body weight). In group IV,
mitomycin C was added to the perfusate in three divided
doses at 30 min intervals in a drug concentration of 15
mg/m2. The first dose contained 50% and the following
administrations 25% of the total dose.
After the perfusion the perfusate was removed and the
abdomen was irrigated with sodium chloride for 10 min-
utes. Afterthere, the abdomen was closed in two layers.
Evaluation
Postoperatively, all animals were kept in individual cages.
The animals were kept under standard conditions and
were sacrificed by an overdose of anesthetics and cervical
dislocation on the 10th postoperative day.
All animals were autopsied and peritoneal carcinomatosis
was evaluated qualitatively and quantitatively. The mac-
roscopic tumor nodules were counted. The tumor weight
was determined using a digital balance.
Conventional histology using H&E staining classified
specimens for occurrence of metastases.
Clinical tumor response
Intraperitoneal tumor growth was scored with a semi-
quantitative cancer index [9]. The scoring ranged from 0
to 5 and was performed by 2 independent observers. A
score of 0 meant that there was no tumor growth; a score
of 1 indicated an estimated tumor diameter less than 0.5
cm; a score of 2, a tumor diameter between 0.5 and 1 cm;
a score of 3, a tumor diameter between 1 and 2 cm; a score
of 4, a tumor diameter between 2 and 3 cm; and a score of
5, a tumor diameter of more than 3 cm.
Histologic determination of apoptotic indices of cancer
To determine the extent of apoptosis in the tumor, sam-
ples were fixed in 10% buffered formaline (pH 6,9–7.1).
From each paraffin-embedded sample, 5 μm thick sec-
tions were prepared and stained with hematoxylin and
eosin (H&E) for light microscopic examination. The 3'-
end labelling of apoptotic cell DNA was performed with
an ApopTag in situ apoptosis kit according to the recom-
mended procedures of the Kit (Roche Diagnostics, Man-
nheim, Germany (in situ cell death detection kit)).
The mean number of apoptotic cells and bodies in the
entire cancer cell population was determined by counting
their numbers in 5 high-power fields of non-necrotic
areas. The index represented the number of visible apop-
totic cancer cells in these fields.
Statistical analysis
Data were analyzed using SPSS/PC+ statistical software.
The mean scores were calculated. All data are presented as
the mean value and standard deviation errors in the single
groups. For comparison of tumor volume and microvessel
density between the diffent groups a non-parametric test
was used (Kruskal-Wallis). Differences were considered
significant at a calculated p value of less than 0.05.
Results
The location and diameter of peritoneal metastasis did
not differ significantly among the four treatment groups
(II-V) at the time of treatment. Before the intervention
diameter of the treated tumors was 5 mm. There were only
one tumor in all cases.
Neither sudden deaths occurred postoperatively nor did
any animal had to be sacrified because of adverse effects.
All animals could be evaluated 10 days following surgery.
Tumor load
In group I, all animals developed extensive intraperito-
neal tumor growth. In group IV, no macroscopic tumor
were found in 2 rats, in three rats only locally limited
metastases were found. These tumors were significantly
smaller than in all other groups (p < 0,02). No diffuse
peritoneal spread was found in group IV.
The mean values of peritoneal cancer index in group I was
3,5. In group II the incidence of metastases spread was sig-
nificantly higher than in group I (p < 0.05). Diffuse peri-
toneal carcinomatosis was found in all animals of group I
and group II. The cancer indices were significantly lower
in group III and in group V compared with group I. The
lowest tumor load was observed in group IV. No signifi-BMC Cancer 2006, 6:162 http://www.biomedcentral.com/1471-2407/6/162
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cant differences in total tumor load was found between
group III and group V.
The tumor scores from group I-V are given in Fig 1.
Tumor weight
Median total tumor weight (local metastases and tumor
spread) in group I were 8,1 g ± 3,4 g. The median weight
of total tumor in group II was significantly higher (16,4 g
± 5,6 g). Total tumor weight in group III and group V was
significantly lower (5,9 g ± 2,8 g and 5,7 g ± 2,4 g, respec-
tively). Lowest total tumor weight was found in group IV
(1,8 g ± 0,9 g mg) (P < 0.05). There was no difference in
tumor weight in group III and group V.
Tumor median nodules 10 days after intervention were 35
± 12 in group I and 68 ± 17 in group II (p < 0.05). The Sig-
nificantly lowest number of tumor nodules were found in
group IV with 4 ± 7. In group III and group V tumor nod-
ules were 21 ± 9 and 16 ± 10, respectively.
The median amount of ascites in the control group (3/5
animals) was 1,34 ml (0–3,2 ml), and 3,21 ml (1,2–4,9
ml) in group II (5/5 animals) was. Ascites was not
detected in any animal in group III, IV and V.
Clinical response
In groups I, II and III in all six animals tumor growth was
seen macroscolicaly. In group V 1/6 animals showed a
complete response of disease. In group IV 4/6 animals had
a clinically total tumor remission.
Histologic findings
In conventional histology (H&E), the tumors in groups I
and II showed no morphological differences. Tumors
were found to be adenocarcinoma with a moderate differ-
entation, mainly tubular structures, vacuolar lumen for-
mation and fibrous septa. Spontaneous necrosis rate
ranged between aproximately 30 and 40%. Tumor mor-
phology did not change with the tumor size.
In group IV the tumors showed signs of irreversible cell
damage after treatment. Tumor cells displayed clear
shrinkage and partial loss of cell contact. Thromboses of
the larger adjacent vessels were found on the tumor-mus-
cle border. Infiltration with macrophages was present in
groups III and IV, but was more pronounced in group IV.
In group III there were less signs of irreversible cell dam-
age after treatment than in group IV (Table 1).
In group I, II and III and V in all animals vital tumor was
found. In group IV in 4/6 animals vital tumor was found.
The zones of viable tumor cells were located in the center
of the tumor. The zones of apoptosis in group IV was
about 3 mm in mean from the tumor margin. Two ani-
mals out of six showed no vital tumor. In groups III and V
no clear zones were seen.
Table 1 shows the kinetics of tumor apoptosis induced by
each treatment. The semiquantitative assessment of
immunhistological stainings revealed a significantly
higher apoptosis level in group IV (Fig. 2) compared to
group I (Fig. 3) and II 10 days after intervention (p =
0,01). The maximum of induced apoptosis was highest in
group IV (p < 0.036). The apoptotic cells located wide-
spread in the tumor margin.
Table 1: Tumor response in group I (control; n = 6), II (HIPEC; n = 6), and III (MMC only; n = 6) 10 days after intervention. * p < 0.05 
group IV versus group I; § p < 0.05 group V versus group I (Kruskal-Wallis test)
Group I Group II Group III Group IV Group V
Tumor weight (g) 8,1 ± 3,4 16,4 ± 5,6 5,9 ± 2,8 1,8 ± 0,9 * 5,7 ± 2,4§
Tumour nodules 35 ± 12 68 ± 17 21 ± 9 4 ± 7 * 16 ± 10§
Cancer index 3,5 4,2 2,2 1,4 * 2,6
Clinical CR 0/6 0/6 0/6 4/6 1/6
Histological CR 0/6 0/6 0/6 2/6 0/6
The mean number of apoptotic cells in 5 high-power fields of  non-necrotic areas Figure 1
The mean number of apoptotic cells in 5 high-power fields of 
non-necrotic areas. (group I: control; group II: sham oper-
ated animals; group III: hyperthermia alone; group IV: HIPEC; 
group V: MMC i.p. alone) * p < 0.036 group IV versus group 
I; (Kruskal-Wallis test)
0,0
5,0
10,0
15,0
20,0
25,0
30,0
I II III IV V
* 
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Different expression levels in group III and group V were
not detectable after 10 days (p > 0,05)
Discussion
Peritoneal carcinomatosis represents a large problem in
the treatment of colorectal carcinomas. A new therapeutic
option is HIPEC. The advantage of HIPEC is that thecyto-
static drug, unlike systemic chemotherapy, can be deliv-
ered directly into the abdominal cavity. The hyperthermic
aspect of the therapy results in an additive effect for the
destruction of tumor cells.
Recent clinical findings suggest that HIPEC is a very prom-
ising therapeutic option. Many authors were able to dem-
onstrate improved chances for survival in selected patient
groups [10-14]. Clinical trials are, however, based on non-
homogenous and non-standardized groups. Additionally,
the only possibilities for evaluating actual tumor response
are indirect, through imaging procedures and survival
rates.
Because of the promising clinical results, it is worthwhile
to study HIPEC under experimental conditions. The pri-
mary parameters would be the histological and morpho-
logical changes in peritoneal carcinomatosis after HIPEC.
A previously published study of locally limited peritoneal
carcinomatosis in a rat model, in which HIPEC could be
performed with long term survival [7], provided the basis
for these experiments. This tumor model is very similar in
its biological traits to that of human colorectal carcino-
mas.
A phenomenon that has been described is the rapid
increase of tumor growth following surgical manipula-
tion.
This was also observed in our sham-operated group of
animals in which tumors grew more rapidly than in the
control group. This implies that resection is associated
with an accelerated growth in residual tumors. It is
assumed that the surgical manipulation induces libera-
Immunohistochemical staining group I (control) Figure 3
Immunohistochemical staining group I (control): Apoptosis 
are represented by red clusters. The index represented the 
number of visible apoptotic cancer cells in five fields
Immunohistochemical staining for group IV (HIPEC) Figure 2
Immunohistochemical staining for group IV (HIPEC): Apop-
tosis are represented by red clusters. The index represented 
the number of visible apoptotic cancer cells in five fields.BMC Cancer 2006, 6:162 http://www.biomedcentral.com/1471-2407/6/162
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tion of growth factors that in addition to their effect on
healing also have a stimulating effect on tumor prolifera-
tion.
In order to better examine the individual aspects of the
effects of HIPEC, two groups were added in addition to
group IV; these groups investigated the two noxa (cyto-
statics and hyperthermia) individually (group III: hyper-
thermic perfusion without MMC; group V: MMC as
mono-therapy). Two control groups were used for com-
parison with the treatment groups, so that the natural pro-
gression of peritoneal carcinomatosis could be pursued.
To come as close as possible to the clinical situation, the
same parameters were used for the experimental per-
fusions as are used in clinical treatment. The only differ-
ence was the lower dose of MMC, as other research groups
have already shown that the experimental tumor can be
completely eradicated by using an equivalent dose. The
ratio of clinical MMC dose HIPEC/mono-therapy was,
however, maintained [7].
The MMC dose was not set too high, as can be seen from
our results. Thus, a therapeutic effect could be recognized
in group 5, although all animals did experience clinical
tumor progression. Histological results showed that in
addition to areas of tumor necrosis and clearly apoptotic
zones, there were also many areas with viable tumor cells.
It was not possible to destroy the tumor in any animal
completely by application of MMC alone.
Similar results were observed in group III. This group also
showed a significant slowing of tumor growth and devel-
opment of peritoneal. However, tumor regression could
be observed in all animals in this group. Histological
results were similar to those from group V and showed
partial damage to the tumor tissue. Complete destruction
of the tumor and thus a definitive therapy could not be
achieved.
The results of groups III and V demonstrate clearly that a
combination of the two components is necessary. The
results from group IV show that the benefits of combina-
tion therapy are not limited to a further significant reduc-
tion in growth rate as compared to groups III and V.
Complete eradication of the tumor with no histological
indication of viable tumor cells was possible in two of six
animals. The size of the treated tumor decreased signifi-
cantly in these two. Although there was also a clinical
reduction in tumor size in the other two animals, viable
tumor cells could still be identified after HIPEC in these
two of six animals. This supports the findings of other
working groups, who showed that HIPEC is best suited for
tumors smaller than 5 mm because of the limited depth
of penetration [15] This size (5 mm) was the chosen
tumor size in our experiments. The results emphasize the
importance of performing HIPEC in a clinical setting only
after radical cytoreduction.
The present study also demonstrates the limits of this new
therapy. Complete eradication of tumors after experimen-
tal HIPEC was not possible in all animals. Despite definite
slowing of tumor growth and inhibition of diffuse perito-
neal seeding over a 10 days' period, further improvements
for the optimization of HIPEC, such as new cytostatic
drugs, must be sought. Moreover, the results show that
clinical reduction of tumor mass is not necessarily associ-
ated with a relapse-free course of disease in this animal
model.
Conclusion
In this study the effect of HIPEC on peritoneal carcinoma-
tosis of colorectal tumors could be investigated in a long-
term standardized animal model. Results showed that
tumor growth was significantly slowed and, in some cases,
completely arrested. However, these experiments also
showed that therapy which appears to have been clinically
successful residual areas of viable tumor cells, maybe left
which lead to recurrence of the disease.
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